InMed shares rise 12.20% premarket after positive cannabinoid R&D advancements and Alzheimer’s study progress.

InMed Pharmaceuticals surged 12.20% in premarket trading following reports of promising cannabinoid R&D advancements, particularly pharmacokinetic study results for its Alzheimer’s drug candidate INM-901. The news highlighted progress in clinical trials and potential future human trials, fueling investor optimism. Financial metrics underscored the company’s early-stage challenges but noted strong liquidity ratios, reinforcing confidence in its R&D-driven growth trajectory. The movement aligns with the cited R&D developments, which directly correlate to the stock’s upward momentum in premarket sessions.